Home
Who We Are
What We Do
Corporate Responsibility
News
Careers
Investors
Patients and HCPS
Contact us
Careers | Investors | Patients and HCPS | Contact us
Careers Investors Patients and HCPS Contact us
Home / Company News / Gan & Lee Pharmaceuticals Announces the Approval of Insulin Aspart (Rapilog) in Bangladesh
Gan & Lee Pharmaceuticals Announces the Approval of Insulin Aspart (Rapilog) in Bangladesh
Date:2022-05-26

BEIJING, CHINA, May 26, 2022 —, Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087. SH) is pleased to announce that the locally filled Insulin Aspart finished product co-produced by Gan & Lee and the local partner in Bangladesh has been approved by the Bangladesh Directorate General of Drug Administration (DGDA).

 

According to the International Diabetes Federation (IDF) Atlas 10th edition, as of 2021, about 13.1 million adults (aged 20 to 79) have been diagnosed with diabetes in Bangladesh, accordingly, Bangladesh ranks 2nd in the incidence of diabetes in Southeast Asia1.


The approved Insulin Aspart Injection (trade name: Rapilog) is a rapid-acting insulin analog, also known as mealtime insulin. It can be injected immediately before or after a meal, which can be quickly absorbed after injection. Insulin Aspart prefilled pen is a single-use injection device that contains a prefilled 3mL Insulin Aspart cartridge which needs to be used with an injection pen needle.

 

Insulin Aspart has become a particularly important mealtime insulin in the treatment of diabetes. Compared with soluble Human Insulin, Insulin Aspart has a faster onset and a shorter duration of action after subcutaneous injection, which is more suitable for the human body’s physiological insulin secretion patterns after meals.

 

The approval of Insulin Aspart brings more treatment options to Bangladeshi patients with diabetes. This is an important milestone for Gan & Lee’s aspart products and technologies as it marks their going global for the first time and it may offer treatment choices to overseas patients.

 

Reference:

1. IDF Diabetes Atlas 10th edition 2021. Available at: https://diabetesatlas.org/atlas/tenth-edition/


About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin®25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely the reusable insulin injection pen (GanleePen™), and the disposable pen needle (GanleeFine®).

 

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 




Copyright © 2021 Gan & Lee Pharmaceuticals Co Ltd . All Rights Reserved.
Our websites

Subscribe

I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.